|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Phosphodiesterase-4 (PDE-4) Inhibitors
La Merie Publishing, Jan 2010, Pages: 24
The present Competitive Intelligence Report about PDE-4 Inhibitors provides a competitor evaluation in the field of small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4) as of January 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for diseases including chronic obstructive pulmonary disease. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and modulation of sensory nerves in the lung as well. Unfortunately, however many PDE-4 inhibitors have failed in early development due to low therapeutic ratios.
Several PDE-4 inhibitors have advanced to late stage clinical development or under regulatory review for treatment of pulmonary or inflammatory bowel diseases. Other inflammatory disease for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, multiple sclerosis and allergic rhinitis. Age-associated memory impairment and Alzheimer’s disease are also studied clinically as indications for PDE-4 inhibitors.
The report includes a compilation of currently active projects in research and development of predominantly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4). In addition, the report lists company-specific R&D pipelines of PDE-4 inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Competitor Analysis - PI3K-AKT-mTOR Inhibitors
Competitor Analysis: Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease
Competitor Analysis: HDAC Inhibitors 2011
Competitor Analysis - p38 MAPK Inhibitors 2010
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors
Competitor Analysis - Janus Kinase (JAK) Inhibitors 2010
Competitor Analysis: Janus Kinase (JAK) Inhibitors
Competitor Analysis: Elastase Inhibitors
Competitor Analysis: Proteasome Inhibitors
Advances in Alzheimer’s Disease Drug Discovery
|
|
|
|
